The Study of Efficacy, Tolerability and Safety of @entity2544 Given Along with @entity6410 Plus @entity4184 in XXXX .

@entity1 @entity32 @entity2544 @entity15687 @entity1353 @entity4184 @entity1030 @entity230 @entity6410 @entity479
BACKGROUND: @entity1030 ( @entity1030 ) is a common disease causing significant socioeconomic burden. @entity1030 @entity1 , commonly smokers develop resistance to inhaled @entity230 attributed to deficiency of @entity15687 ( @entity15687 ). The study of relationship between systemic @entity32 and functional performance demonstrated that increased CRP level is inversely related to six minute walk distance (SMWD) and Forced Expired Volume in one second (FEV1). @entity2544 restores @entity15687 activity thereby unlocking @entity479 resistance and potentiating inhaled corticosteroids (ICS) action culminating in reduced airway @entity32 and mortality. AIM: To study the effects of addition of @entity2544 to the combination of @entity6410 plus @entity4184 on various objective and subjective parameters in moderate to severe @entity1030 @entity1 and to assess the safety profile of the combination. Setting and Study design: A single blinded, prospective, randomized, placebo controlled study at a tertiary care hospital in Jaipur, India. MATERIALS AND METHODS: Fifty eight @entity1 diagnosed with moderate to severe @entity1030 were randomized into two groups. Group A @entity1 received @entity6410 24 g plus @entity4184 800 g daily in divided doses along with @entity2544 while group B @entity1 received @entity6410 24 g plus @entity4184 800 g daily in divided doses along with placebo tablets. Both groups were followed up on 15th, 30th _60th day. During every visit all @entity1 were assessed subjectively (symptom scoring) and objectively (spirometry, CRP, SMWT) and adverse effects if any were recorded. The obtained data subject to statistical analysis using"Graph pad Instat3" software. RESULTS: Statistically significant improvement with a decline in total symptom score (p < 0.0001) was found with respect to "Night symptoms"_"SOB on rising" in group A. @entity2544 group showed significant improvement in SMWD and FEV1.Mean fall in CRP was greater in Group A (not statistically significant). No side effects requiring withdrawal of drug were noted with @entity2544 . CONCLUSION: Addition of @entity2544 to @entity6410 plus @entity4184 reduces @entity1353 , improves exercise performance and pulmonary functions in moderate to severe @entity1030 . Further studies are required to explore if reduced dosage would have equal efficacy with better safety and tolerability profile.
